Results Have Been Submitted Ahead of In-Person Meeting with FDA Set for April 2CTx-1301 is the First, True, Once-Daily Stimulant Medication to ...
Zacks Small Cap Research on MSN7d
CING: April Pre-NDA MeetingCING READ THE FULL CING RESEARCH REPORT Since the report of third quarter results, Cingulate, Inc. (NASDAQ:CING) has executed ...
Cingulate (CING) released Phase 3 safety data for its lead asset CTx-1301 for the treatment of Attention Deficit Hyperactivity Disorder, ADHD.
Cingulate Inc. submitted CTx-1301 Phase 3 safety data to the FDA, preparing for a Pre-NDA meeting on April 2, 2025. Cingulate Inc. announced the submission of Phase 3 safety data for its ADHD ...
Hosted on MSN21d
FDA Breakthrough: First-Ever Treatment Approved for Rare and Devastating CTX Disorder!CTX stems from a genetic mutation in the CYP27A1 gene, resulting in a deficiency of an enzyme essential for lipid breakdown. This deficiency disrupts bile acid production in the liver, preventing ...
After asset purchase from Travere, Mirum's Ctexli crosses FDA finish line in rare metabolic disorder
The FDA on Friday gave the green light to Mirum’s Ctexli, also known as chenodiol, for the treatment of adults with cerebrotendinous xanthomatosis (CTX). The approval makes chenodiol—already ...
(Nasdaq: MIRM) today announced that the U.S. Food and Drug Administration (FDA) has approved CTEXLI™ (chenodiol) tablets, a bile acid, for the treatment of adults with cerebrotendinous xanthomatosis ...
“The safety data from these three studies has been reviewed thoroughly, and we are pleased that the safety profile of CTx-1301 has remained remarkably consistent and unprecedented over the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback